Where do Europeans wait longest for new medicines?

European access to new medicines is deteriorating: full public reimbursement coverage fell to 28% in 2025 from 42% in 2019, and the median time to availability is 532 days after marketing authorisation. Access gaps are wide, with Germany at 56 days versus Romania at 1,201 days, while 37% of U.S.-approved medicines from 2016-2025 still lack EMA approval. The report points to slower EU regulatory processes and worsening availability across Northern and Eastern Europe.

Analysis

The key market implication is not simply that Europe is ‘slow’ on approvals; it is that the region is becoming a structurally worse monetization venue for innovation. That shifts value capture toward US-centric launch sequencing, makes ex-Europe commercialization less meaningful for marginal R&D economics, and increases the probability that smaller biotech pipelines will prioritize FDA-first strategies while treating Europe as optionality rather than a core revenue pool.

Second-order, this is most negative for companies whose near-term growth cases depend on broad EU reimbursement uptake, especially orphan and specialty assets where country-level fragmentation can materially cap peak sales and delay inflection points by 1-3 years. It is also a subtle headwind for European healthcare payers and hospital systems: delayed access may look cost-saving in the short run, but it raises downstream acute-care burden and creates political pressure for reactive reform rather than proactive harmonization.

For data and commercial infrastructure names, the read-through is mixed. Near-term, slower and more uneven launches can increase demand for market-access analytics, evidence-generation, and country-by-country payer negotiation tools, which should support vendors exposed to launch sequencing and real-world evidence. But over a multi-year horizon, if Europe continues to lose launch share, the absolute pool of addressable post-approval services may shrink versus the US and China, so the benefit is more about mix than secular growth.

Consensus may be underestimating how sticky the divergence is: once sponsors start de-prioritizing Europe in launch planning, the region can fall into a negative-feedback loop of fewer launches, less commercial attention, weaker local evidence generation, and still slower access. The catalyst to watch is not another policy headline, but whether a meaningful share of 2025-2026 FDA approvals skip or materially delay EMA filing; that would confirm a real strategic rerouting of innovation and be bearish for Europe’s life-sciences ecosystem beyond the initial headline effect.

Key Decisions for Investors

• Underweight European specialty-pharma and orphan-exposed names versus US peers over the next 6-12 months; the risk is slower ex-US revenue ramp and lower peak-sales realization if EU reimbursement delays persist.
• Long IQV on a 6-12 month horizon if the market is not fully pricing in greater demand for launch analytics, evidence generation, and market-access workflow tools; use pullbacks to add, with a stop if EU launch slippage fails to translate into higher services spend.
• Pair trade: long US large-cap biotech basket / short EU pharma basket for 3-6 months; thesis is that FDA-first economics and faster commercialization will widen valuation dispersion as Europe becomes less relevant to early pipeline value capture.
• Avoid adding to Europe-facing launch-dependent biotech before the next reimbursement cycle; the risk/reward is poor until there is evidence of faster country-level adoption or actual harmonization, which likely takes multiple quarters.